Microencapsulation of vaccine antigens and adjuvants for mucosal targeting

Current Immunology Reviews

Volumn 6, Issue 1, 2010, Pages 29-37

  Rajapaksa, Thejani E ^a   Lo, David D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

M cell targeting; Microparticles; PLGA

Indexed keywords

ATRASENTAN; BACTERIAL ANTIGEN; BOTULINUM ANTISERUM; CHITOSAN; CLOSTRIDIUM PERFRINGENS EXOTOXIN; CPG OLIGODEOXYNUCLEOTIDE; EXOTOXIN; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIGAND; MALARIA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NKM 16 2 4; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OVALBUMIN; POLOXAMER; POLYGLACTIN; POLYMER; POLYVINYL ALCOHOL; REOVIRUS PROTEIN SIGMA; TETANUS TOXOID; ULEX EUROPAEUS AGGLUTININ; UNCLASSIFIED DRUG; VACCINE; VIRUS ANTIGEN; VIRUS PROTEIN;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG UPTAKE; EPITHELIUM CELL; HUMAN; INFECTION PREVENTION; LYMPHOID TISSUE; M CELL; MICROENCAPSULATION; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; TARGET ORGAN;

EID: 77949742766     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339510790231798     Document Type: Review

References (63)

1. Jepson MA, Clark MA, Foster N, et al. Targeting to intestinal M cells. J Anat 1996; 189: 507-16.
2. Sansonetti PJ, Phalipon A. M cells as ports of entry for enteroinvasive pathogens: mechanisms of interaction, consequences for the disease process. Semin Immunol 1999; 11: 193-203.
3. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 2007; 15:701-13.
4. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 307: 254-8.
5. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2: 361-7.
6. Bye WA, Allan CH, Trier JS. Structure, distribution, and origin of M cells in Peyer's patches of mouse ileum. Gastroenterology 1984; 86: 789-801.
7. Ermak TH, Steger HJ, Pappo J. Phenotypically distinct subpopulations of T cells in domes and M-cell pockets of rabbit gut-associated lymphoid tissues. Immunology 1990; 71: 530-7.
8. van der Lubben IM, van Opdorp FA, Hengeveld MR, et al. Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model. J Drug Target 2002; 10: 449-56.
9. Ermak TH, Dougherty EP, Bhagat HR, Kabok Z, Pappo J. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells. Cell Tissue Res 1995; 279: 433-6.
10. Pappo J, Ermak TH. Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake. Clin Exp Immunol 1989; 76: 144-8.
11. Rafati H, Lavelle EC, Coombes AG, Stolnik S, Holland J, Davis SS. The immune response to a model antigen associated with PLG microparticles prepared using different surfactants. Vaccine 1997; 15: 1888-97.
12. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005; 57: 391-410.
13. Rosas JE, Hernandez RM, Gascon AR, et al. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. Vaccine 2001; 19: 4445-51.
14. Lavelle EC, Yeh MK, Coombes AG, Davis SS. The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine 1999; 17: 512-29.
15. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991; 59: 2978-86.
16. Hora MS, Rana RK, Nunberg JH, Tice TR, Gilley RM, Hudson ME. Release of human serum albumin from poly(lactide-coglycolide) microspheres. Pharm Res 1990; 7: 1190-4.
17. Zhang JX, Chen D, Wang SJ, Zhu KJ. Optimizing double emulsion process to decrease the burst release of protein from biodegradable polymer microspheres. J Microencapsul 2005; 22: 413-22.
18. Cohen S, Alonso MJ, Langer R. Novel approaches to controlled-release antigen delivery. Int J Technol Assess Health Care 1994; 10: 121-30.
19. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21: 2475-90.
20. Jalil R, Nixon JR. Biodegradable poly(lactic acid) and poly(lactide-coglycolide) microcapsules: problems associated with preparative techniques and release properties. J Microencapsul 1990; 7: 297-325.
21. Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull (Tokyo) 1988; 36: 1095-103.
22. Coombes AG, Yeh MK, Lavelle EC, Davis SS. The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release 1998; 52: 311-20.
23. Murillo M, Irache JM, Estevan M, Goni MM, Blasco JM, Gamazo C. Influence of the co-encapsulation of different excipients on the properties of polyester microparticle-based vaccine against brucellosis. Int J Pharm 2004; 271: 125-35.
24. Phillips B, Nylander K, Harnaha J, et al. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 2008; 57: 1544-55.
25. Mao S, Shi Y, Li L, Xu J, Schaper A, Kissel T. Effects of process and formulation parameters on characteristics and internal morphology of poly(d,l-lactide-co-glycolide) microspheres formed by the solvent evaporation method. Eur J Pharm Biopharm 2008; 68: 214-23.
26. Leo E, Pecquet S, Rojas J, Couvreur P, Fattal E. Changing the pH of the external aqueous phase may modulate protein entrapment and delivery from poly(lactide-co-glycolide) microspheres prepared by a w/o/w solvent evaporation method. J Microencapsul 1998; 15: 421-30.
27. Gaumet M, Gurny R, Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur J Pharm Sci 2009; 36: 465-73.
28. Zhang X, Sharma KK, Boeglin M, et al. Transfection ability and intracellular DNA pathway of nanostructured gene-delivery systems. Nano Lett 2008; 8: 2432-6.
29. Singh M, Singh O, Talwar GP. Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys. Pharm Res 1995; 12: 1796-800.
30. Blanco D, Alonso MJ. Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants. Eur J Pharm Biopharm 1998; 45: 285-94.
31. Shakweh M, Besnard M, Nicolas V, Fattal E. Poly (lactide-coglycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur J Pharm Biopharm 2005; 61: 1-13.
32. Al Haushey L, Bolzinger MA, Bordes C, Gauvrit JY, Briancon S. Improvement of a bovine serum albumin microencapsulation process by screening design. Int J Pharm 2007; 344: 16-25.
33. Fujimura Y, Akisada T, Harada T, Haruma K. Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol 2006; 39: 181-6.
34. Ahire VJ, Sawant KK, Doshi JB, Ravetkar SD. Chitosan microparticles as oral delivery system for tetanus toxoid. Drug Dev Ind Pharm 2007; 33: 1112-24.
35. Li X, Kong X, Shi S, et al. Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol 2008; 8: 89.
36. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51: 81-96.
37. San Roman B, Irache JM, Gomez S, Tsapis N, Gamazo C, Espuelas MS. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm 2008; 70: 98-108.
38. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001; 50: 81-106.
39. Eldridge JH, Gilley RM, Staas JK, Moldoveanu Z, Meulbroek JA, Tice TR. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbiol Immunol 1989; 146: 59-66.
40. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 2009; 30: 2790-8.
41. Frey A, Giannasca KT, Weltzin R, et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 1996; 184: 1045-59.
42. Foster N, Clark MA, Jepson MA, Hirst BH. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 1998; 16: 536-41.
43. Manocha M, Pal PC, Chitralekha KT, et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005; 23: 5599-617.
44. McClean S, Prosser E, Meehan E, et al. Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur J Pharm Sci 1998; 6: 153-63.
45. Roth-Walter F, Bohle B, Scholl I, et al. Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. Immunol Lett 2005; 100: 182-8.
46. Roth-Walter F, Scholl I, Untersmayr E, et al. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 2005; 23: 2703-10.
47. Lambkin I, Pinilla C, Hamashin C, et al. Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries. Pharm Res 2003; 20: 1258-66.
48. Helander A, Silvey KJ, Mantis NJ, et al. The viral sigma1 protein and glycoconjugates containing alpha2-3-linked sialic acid are involved in type 1 reovirus adherence to M cell apical surfaces. J Virol 2003; 77: 7964-77.
49. Suzuki H, Sekine S, Kataoka K, et al. Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells. Gastroenterology 2008; 135: 917-25.
50. Rubas W, Banerjea AC, Gallati H, Speiser PP, Joklik WK. Incorporation of the reovirus M cell attachment protein into small unilamellar vesicles: incorporation efficiency and binding capability to L929 cells in vitro. J Microencapsul 1990; 7: 385-95.
51. Wu Y, Boysun MJ, Csencsits KL, Pascual DW. Gene transfer facilitated by a cellular targeting molecule, reovirus protein sigma1. Gene Ther 2000; 7: 61-9.
52. Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW. M cell-targeted DNA vaccination. Proc Natl Acad Sci USA 2001; 98: 9318-23.
53. Nochi T, Yuki Y, Matsumura A, et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 2007; 204: 2789-96.
54. Kuo WL, Lee LY, Wu CM, et al. Differential expression of claudin-4 between intestinal and diffuse-type gastric cancer. Oncol Rep 2006; 16: 729-34.
55. Lo D, Tynan W, Dickerson J, et al. Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures. Int Immunol 2004; 16: 91-9.
56. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 2001; 120: 411-22.
57. Ling J, Liao H, Clark R, Wong MS, Lo DD. Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. J Biol Chem 2008; 283: 30585-95.
58. Nayak B, Panda AK, Ray P, Ray AR. Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination. J Microencapsul 2009; 26: 154-65.
59. Hilbert AK, Fritzsche U, Kissel T. Biodegradable microspheres containing influenza A vaccine: immune response in mice. Vaccine 1999; 17: 1065-73.
60. Marazuela EG, Prado N, Moro E, et al. Intranasal vaccination with poly(lactide-co-glycolide) microparticles containing a peptide T of Ole e 1 prevents mice against sensitization. Clin Exp Allergy 2008; 38: 520-8.
61. Shi L, Caulfield MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci 2002; 91: 1019-35.
62. Kirby DJ, Rosenkrands I, Agger EM, Andersen P, Coombes AG, Perrie Y. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target 2008; 16: 282-93.
63. Wack A, Baudner BC, Hilbert AK, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008; 26: 552-61.